Phase I and pharmacokinetic study of BIBX 1382, an EGFR inhibitor, as continuous daily oral administration.

被引：0
|
作者：
Dittrich, C
Bruntsch, U
Borner, M
Weigang, K
Huisman, H
Amelsberg, A
Wanders, J
Hanauske, A
Fumoleau, P
机构：
[1] Ctr Rene Gauducheau, F-44035 Nantes, France
[2] Tech Univ Munich, D-8000 Munich, Germany
[3] Boehringer Ingelheim KG, Biberach, Germany
[4] NDDO Oncol, Amsterdam, Netherlands
[5] Univ Bern, Inselspital, Dept Oncol, CH-3010 Bern, Switzerland
[6] 5th Med Clin, Nurnberg, Germany
[7] KFJ Spital, LBI ACR VIE, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2000年 / 11卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
608PD
引用
收藏
页码：133 / 133
页数：1
相关论文
共 50 条
  • [1] Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration
    Dittrich, C
    Greim, G
    Borner, M
    Weigang-Köhler, K
    Huisman, H
    Amelsberg, A
    Ehret, A
    Wanders, J
    Hanauske, A
    Fumoleau, P
    EUROPEAN JOURNAL OF CANCER, 2002, 38 (08) : 1072 - 1080
  • [2] A phase I and pharmacokinetic (PK) study of continuous daily administration of P1446A-05, a potent and specific oral Cdk4 inhibitor.
    Hao, Desiree
    Chu, Quincy
    Welch, Stephen
    Yau, Cindy Y. F.
    Spratlin, Jennifer L.
    Tang, Patricia
    MacKenzie, Mary J.
    Townsley, Carol A.
    Arndt, Diane
    Johnson, Laureen
    Trapsa, Daniela
    Degendorfer, Pamela
    Kulkarni, Sujay
    Jawlekar, Gajendra
    Dhobe, Poornima
    Oza, Amit M.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Phase I study of the oral CDK-TRKA inhibitor PHA-848125 administered with prolonged schedules of administration.
    Cresta, S.
    Sessa, C.
    Del Conte, G.
    Locatelli, A.
    Gallerani, E.
    Florentini, F.
    Scaburri, A.
    Pacciarini, M. A.
    Alzani, R.
    Gianni, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [4] Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer
    Cohen, SJ
    Leichman, CG
    Yeslow, G
    Beard, M
    Proefrock, A
    Roedig, B
    Damle, B
    Letrent, SP
    DeCillis, AP
    Meropol, NJ
    CLINICAL CANCER RESEARCH, 2002, 8 (07) : 2116 - 2122
  • [5] A phase I and pharmacokinetic (PK) study of BIBW 2992, an oral irreversible dual EGFR/HER2 inhibitor
    Plummer, R.
    Vida, L.
    Perrett, R.
    Spicer, J.
    Stopfer, P.
    Shahidi, M.
    Temple, G.
    Futreal, A.
    Calvert, H.
    de Bono, J.
    EJC SUPPLEMENTS, 2007, 5 (04): : 108 - 108
  • [6] A PHASE-I CLINICAL AND PHARMACOKINETIC STUDY OF THE ORAL AND THE ORAL INTRAVENOUS ADMINISTRATION OF MENOGARIL
    WEISS, GR
    BROWN, TD
    KUHN, JG
    VONHOFF, DD
    EARHART, RH
    ADAMS, WJ
    BREWER, JE
    HOSLEY, JD
    KASUNIC, DA
    INVESTIGATIONAL NEW DRUGS, 1993, 11 (01) : 17 - 27
  • [7] Continuous administration of irinotecan by hepatic arterial infusion: A phase I and pharmacokinetic study
    van Riel, JMGH
    van Groeningen, CJ
    Kedde, MA
    Gall, H
    Leisink, JMA
    Gruia, G
    Pinedo, HM
    van der Vijgh, WJF
    Giaccone, G
    CLINICAL CANCER RESEARCH, 2002, 8 (02) : 405 - 412
  • [8] Phase I clinical and pharmacokinetic study of oral carboxyamidotriazole, a signal transduction inhibitor
    Berlin, J
    Tutsch, KD
    Hutson, P
    Cleary, J
    Rago, RP
    Arzoomanian, RZ
    Alberti, D
    Feierabend, C
    Wilding, G
    JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (02) : 781 - 789
  • [9] Phase I and pharmacokinetic study of oral paclitaxel
    Malingré, MM
    Terwogt, JMM
    Beijnen, JH
    Rosing, H
    Koopman, FJ
    van Tellingen, O
    Duchin, K
    Huinink, WWT
    Swart, M
    Lieverst, J
    Schellens, JHM
    JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (12) : 2468 - 2475
  • [10] Pharmacodynamics and pharmacokinetics of continuous omeprazole infusion followed by once- or twice-daily oral administration.
    Thomson, ABR
    Hasselgren, G
    Keelan, M
    Lee, J
    Matisko, A
    Sinclair, P
    Röhss, K
    GASTROENTEROLOGY, 1998, 114 (04) : A310 - A310
12345